These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22277093)

  • 1. Single domain antibodies: a new concept for epidermal growth factor receptor and EGFRvIII targeting.
    Omidfar K; Shirvani Z
    DNA Cell Biol; 2012 Jun; 31(6):1015-26. PubMed ID: 22277093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production of a novel camel single-domain antibody specific for the type III mutant EGFR.
    Omidfar K; Rasaee MJ; Modjtahedi H; Forouzandeh M; Taghikhani M; Golmakani N
    Tumour Biol; 2004; 25(5-6):296-305. PubMed ID: 15627895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the epidermal growth factor receptor in solid tumor malignancies.
    Nedergaard MK; Hedegaard CJ; Poulsen HS
    BioDrugs; 2012 Apr; 26(2):83-99. PubMed ID: 22385404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Production and characterization of a new antibody specific for the mutant EGF receptor, EGFRvIII, in Camelus bactrianus.
    Omidfar K; Rasaee MJ; Modjtahedi H; Forouzandeh M; Taghikhani M; Bakhtiari A; Paknejad M; Kashanian S
    Tumour Biol; 2004; 25(4):179-87. PubMed ID: 15557755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting epidermal growth factor receptor in tumors: from conventional monoclonal antibodies via heavy chain-only antibodies to nanobodies.
    Altintas I; Kok RJ; Schiffelers RM
    Eur J Pharm Sci; 2012 Mar; 45(4):399-407. PubMed ID: 22064454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential tumor-targeting abilities of three single-domain antibody formats.
    Bell A; Wang ZJ; Arbabi-Ghahroudi M; Chang TA; Durocher Y; Trojahn U; Baardsnes J; Jaramillo ML; Li S; Baral TN; O'Connor-McCourt M; Mackenzie R; Zhang J
    Cancer Lett; 2010 Mar; 289(1):81-90. PubMed ID: 19716651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy.
    Gan HK; Burgess AW; Clayton AH; Scott AM
    Cancer Res; 2012 Jun; 72(12):2924-30. PubMed ID: 22659454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy.
    Modjtahedi H; Moscatello DK; Box G; Green M; Shotton C; Lamb DJ; Reynolds LJ; Wong AJ; Dean C; Thomas H; Eccles S
    Int J Cancer; 2003 Jun; 105(2):273-80. PubMed ID: 12673691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy of solid tumors by monoclonal antibody specific to epidermal growth factor receptor.
    Baradaran B; Majidi J; Farajnia S; Barar J; Omidi Y
    Hum Antibodies; 2014; 23(1-2):13-20. PubMed ID: 25812698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.
    Wikstrand CJ; Hale LP; Batra SK; Hill ML; Humphrey PA; Kurpad SN; McLendon RE; Moscatello D; Pegram CN; Reist CJ
    Cancer Res; 1995 Jul; 55(14):3140-8. PubMed ID: 7606735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human IgG antibodies recognizing distinct extracellular domains of EGF receptor exhibit different degrees of growth inhibitory effects on human A431 cancer cells.
    Chang C; Takayanagi A; Yoshida T; Shimizu N
    Exp Cell Res; 2013 May; 319(8):1146-55. PubMed ID: 23499740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
    Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
    Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies of thermostability in Camelus bactrianus (Bactrian camel) single-domain antibody specific for the mutant epidermal-growth-factor receptor expressed by Pichia.
    Omidfar K; Rasaee MJ; Kashanian S; Paknejad M; Bathaie Z
    Biotechnol Appl Biochem; 2007 Jan; 46(Pt 1):41-9. PubMed ID: 16848761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation of a human anti-epidermal growth factor receptor Fab antibody, EG-19-11, with subnanomolar affinity from naïve immunoglobulin repertoires using a hierarchical antibody library system.
    Hur BU; Yoon JB; Liu LK; Cha SH
    Immunol Lett; 2010 Nov; 134(1):55-61. PubMed ID: 20797408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A bispecific transmembrane antibody simultaneously targeting intra- and extracellular epitopes of the epidermal growth factor receptor inhibits receptor activation and tumor cell growth.
    Müller N; Hartmann C; Genssler S; Koch J; Kinner A; Grez M; Wels WS
    Int J Cancer; 2014 Jun; 134(11):2547-59. PubMed ID: 24243620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII).
    Klausz K; Berger S; Lammerts van Bueren JJ; Derer S; Lohse S; Dechant M; van de Winkel JG; Peipp M; Parren PW; Valerius T
    Cancer Sci; 2011 Oct; 102(10):1761-8. PubMed ID: 21718386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A collagen-binding EGFR antibody fragment targeting tumors with a collagen-rich extracellular matrix.
    Liang H; Li X; Wang B; Chen B; Zhao Y; Sun J; Zhuang Y; Shi J; Shen H; Zhang Z; Dai J
    Sci Rep; 2016 Feb; 6():18205. PubMed ID: 26883295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
    Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
    Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments.
    Kataoka H
    J Dermatol Sci; 2009 Dec; 56(3):148-53. PubMed ID: 19896805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation of novel EGFR-specific VHH domains.
    Gottlin EB; Xiangrong Guan ; Pegram C; Cannedy A; Campa MJ; Patz EF
    J Biomol Screen; 2009 Jan; 14(1):77-85. PubMed ID: 19171923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.